Patents Assigned to Toyama Chemical Co., Ltd.
  • TABLET COMPRISING 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)ETHOXY)PROPYL)AZETIDIN-3-OL OR SALT THEREOF
    Publication number: 20180369194
    Abstract: A tablet which comprises (1) 1-(3-(2-(1-benzothiophen-5- yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and (2) ethyl cellulose, said tablet having excellent elution properties and good moldability, remaining stable during prolonged storage, and exhibiting high impact resistance.
    Type: Application
    Filed: December 22, 2016
    Publication date: December 27, 2018
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventors: Atsushi KANO, Hiroyuki INABA, Tai OURA
  • Pharmaceutical composition containing hydroxamic acid derivative or salt thereof
    Patent number: 10149911
    Abstract: This pharmaceutical composition contains a hydroxamic acid derivative, or a salt thereof, and a solubilizer, said hydroxamic acid derivative being selected from among (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, 2S)-2-((4-((4-((1R)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, and (2S)-N-hydroxy-2-((4-((4-((1S)-1-hydroxy-2-methoxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N?,2-dimethylmalonamide. The pharmaceutical composition demonstrates strong antibacterial activity, has excellent solubility in water, and is useful as a drug.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 11, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Tatsuya Honda, Yuko Suzumura, Tomoya Kato, Yu Koseki, Kohei Ono
  • Method for using novel hydroxamic acid derivative and antibacterial substance in combination
    Patent number: 10123990
    Abstract: Pharmacological compositions containing a hydroxamic acid derivative selected from (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, (2S)-2-((4-((4-((1R)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, and (2S)—N-hydroxy-2-((4-((4-((1S)-1-hydroxy-2-methoxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N?,2-dimethylmalonamide, or a salt of said derivatives, and an antibiotic substance are useful in the treatment of gram-negative bacterial infections.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: November 13, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Maki Eto, Tori Funatsu, Akiko Nakagawa, Masasuke Fujiwara
  • Methods and pharmaceutical compositions for the treatment of ebola virus disease
    Patent number: 10098879
    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of Ebola Virus Disease. In particular the present relates to a method of treating Ebola Virus Disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of Favipiravir.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: October 16, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BORDEAUX, CHU DE BORDEAUX, TOYAMA CHEMICAL CO., LTD
    Inventors: Denis Malvy, Sylvain Baize, Xavier De Lamballerie, Hervé Raoul, Cédric Laouenan, Jeremie Guedj, France Mentre
  • ANTI-HEPATITIS B VIRUS AGENT
    Publication number: 20180291011
    Abstract: An anti-hepatitis B virus agent comprising a compound represented by general formula [1], wherein R1 represents an aryl group, which may be substituted, or the like; R2 represents an aryl group, which may be substituted, or the like; and R3 represents a hydrogen atom or the like; or a salt thereof.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 11, 2018
    Applicants: TOYAMA CHEMICAL CO., LTD., PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY
    Inventors: Kazuki SHIMANE, Yasuhito TANAKA
  • POST NERVE INJURY REHABILITATION EFFECT-ENHANCING AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF
    Publication number: 20180289668
    Abstract: Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.
    Type: Application
    Filed: June 12, 2018
    Publication date: October 11, 2018
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventors: Takuya Takahashi, Tomohiro Okuda
  • CRYSTALS OF 5-CYCLOPROPYL-2-((1-(3-FLUOROBENZYL)-1H-INDOL-5-YL)AMINO)NICOTINIC ACID
    Publication number: 20180244647
    Abstract: Crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1H-indol-5-yl)amino)nicotinic acid having diffraction peaks at diffraction angles (2?) of 12.2±0.2, 17.2±0.2, 19.4±0.2, 24.1±0.2, and 27.1±0.2° or diffraction angles (2?) of 12.9±0.2, 15.5±0.2, 21.2±0.2, 21.7±0.2, and 25.9±0.2° in powder x-ray diffraction have excellent stability, are easy to handle, and are useful as a drug substance of pharmaceuticals to be used in treatments such as the prevention or treatment of diseases involving keratinocyte hyperproliferation.
    Type: Application
    Filed: August 30, 2016
    Publication date: August 30, 2018
    Applicants: TOYAMA CHEMICAL CO., LTD., FUJIFILM CORPORATION
    Inventors: Yusuke OKUBO, Tadashi TANAKA
  • Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof
    Patent number: 10039744
    Abstract: Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: August 7, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Takuya Takahashi, Tomohiro Okuda
  • SIGMA RECEPTOR-BINDING AGENT
    Publication number: 20180153855
    Abstract: A sigma receptor-binding agent, which comprises an alkyl ether derivative represented by formula [1] or a salt thereof is provided. wherein R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, or the like; R3 represents an optionally protected hydroxyl group or the like; m and n, which are the same or different, each represent an integer of 1 to 6.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 7, 2018
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventor: Takeaki YANO
  • 6-BROMO-3-HYDROXY-2-PYRAZINECARBOXAMIDE CRYSTAL AND METHOD FOR PRODUCING SAME
    Publication number: 20180141920
    Abstract: The purpose of the present invention is to provide a method for producing 6-bromo-3-hydroxy-2-pyrazinecarboxamide in which the content ratio of impurities is reduced. This production method includes a step of obtaining 6-bromo-3-hydroxy-2-pyrazinecarboxamide crystal having diffraction angles expressed in degrees 20 of 5.5, 20.1, 23.7, 26.7, 27.5, and 28.1° and/or diffraction angles expressed in degrees 2? of 7.1, 21.4, 25.2, 25.7, 27.1, and 28.8° in powder X-ray diffraction.
    Type: Application
    Filed: June 8, 2016
    Publication date: May 24, 2018
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventors: Tetsuro UCHIDA, Sayuri UEHARA, Takayoshi TSUZUKI, Yusuke OKUBO, Yuta KOBAYASHI, Yu KOSEKI
  • Prevention or treatment agent for cerebral amyloid beta storage diseases
    Patent number: 9968585
    Abstract: Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid beta storage diseases. This prevention or treatment agent for cerebral amyloid beta storage diseases has as an effective component thereof a compound (e.g., Iguratimod) indicated by formula (1) or a salt thereof and, as a result, is capable of preventing or treating cerebral amyloid beta storage diseases such as Alzheimer-type dementia or cerebral amyloid angiopathy.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: May 15, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventor: Hiroji Yanamoto
  • Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
    Patent number: 9918963
    Abstract: A method for treating the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse, by administering a benzopyran derivative of the following formula or a salt thereof, where R1 represents an optionally substituted C1-6 alkyl group, one of R2 and R3 represents a hydrogen atom, and the other of R2 and R3 represents a hydrogen atom, an optionally substituted amino group, an optionally substituted acylamino group, an optionally substituted carbamoyl group or an optionally substituted aryl group.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: March 20, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Keiichi Tanaka, Kimiko Morimoto
  • Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
    Patent number: 9872914
    Abstract: This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a salt thereof.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: January 23, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Hiroyuki Inaba, Mitsuhiro Nagata
  • Hydroxamic acid derivative or salt thereof
    Patent number: 9862676
    Abstract: A compound represented by general formula (1) (wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group or the like; R3 represents a hydrogen atom or an optionally substituted C1-6 alkyl group; R4 represents a hydrogen atom, an optionally substituted C1-6 alkyl group or the like; X1 represents an optionally substituted C2-6 alkynylene group or the like; A represents an optionally substituted bivalent aromatic hydrocarbon group or the like; X2 represents an optionally substituted C1-6 alkylene group or the like; Y1 represents an oxygen atom or the like; and R5 represents a hydrogen atom or the like) or a salt thereof is useful as an antibacterial agent.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 9, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Muneo Shoji, Naomi Sugaya, Naoko Yasobu
  • METHOD FOR USING NOVEL HYDROXAMIC ACID DERIVATIVE AND ANTIBACTERIAL SUBSTANCE IN COMBINATION
    Publication number: 20170296503
    Abstract: Pharmacological compositions containing a hydroxamic acid derivative selected from (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, (2S)-2-((4-((4-((1R)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N?,2-dimethylmalonamide, and (2S)—N-hydroxy-2-((4-((4-((1S)-1-hydroxy-2-methoxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N?,2-dimethylmalonamide, or a salt of said derivatives, and an antibiotic substance are useful in the treatment of gram-negative bacterial infections.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 19, 2017
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventors: Maki ETO, Tori FUNATSU, Akiko NAKAGAWA, Masasuke FUJIWARA
  • POST NERVE INJURY REHABILITATION EFFECT-ENHANCING AGENT COMPRISING ALKYL ETHER DERIVATIVE OR SALT THEREOF
    Publication number: 20170165227
    Abstract: Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.
    Type: Application
    Filed: January 30, 2015
    Publication date: June 15, 2017
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventors: Takuya TAKAHASHI, Tomohiro OKUDA
  • Amine derivative or salt thereof
    Patent number: 9624215
    Abstract: A novel amine derivative expressed by general formula (1) (in the formula: G1, G2, and G3 are the same or different and represent CH or a nitrogen atom; R1 represents a chlorine atom, an optionally-substituted C3-8 cycloalkyl group, or the like; R2 represents —COOR5 (in the formula, R5 represents a hydrogen atom or a carboxyl protective group), or the like; R3 represents a hydrogen atom, or the like; and R4 represents an optionally-substituted condensed bicyclic hydrocarbon group, an optionally-substituted bicyclic heterocyclic group, or the like), or a salt thereof is useful in procedures such as the treatment or prevention of conditions related to excessive keratinocyte proliferation.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: April 18, 2017
    Assignees: TOYAMA CHEMICAL CO., LTD., FUJIFILM CORPORATION
    Inventors: Tadashi Tanaka, Yoshitake Konishi, Daisuke Kubo, Masataka Fujino, Issei Doi, Daisuke Nakagawa, Tatsuya Murakami, Takayuki Yamakawa
  • PREVENTION OR TREATMENT AGENT FOR CEREBRAL AMYLOID BETA STORAGE DISEASES
    Publication number: 20170049744
    Abstract: Provided is a prevention or treatment agent for cerebral amyloid beta storage diseases, that contains a substance capable of suppressing the progression, alleviating the symptoms, and improving cerebral amyloid beta storage diseases. This prevention or treatment agent for cerebral amyloid beta storage diseases has as an effective component thereof a compound (e.g., Iguratimod) indicated by formula (1) or a salt thereof and, as a result, is capable of preventing or treating cerebral amyloid beta storage diseases such as Alzheimer-type dementia or cerebral amyloid angiopathy.
    Type: Application
    Filed: February 16, 2015
    Publication date: February 23, 2017
    Applicant: TOYAMA CHEMICAL CO., LTD.
    Inventor: Hiroji YANAMOTO
  • Hydroxamic acid derivative
    Patent number: 9499477
    Abstract: Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: November 22, 2016
    Assignees: TOYAMA CHEMICAL CO., LTD., TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Hajime Takashima, Risa Tsuruta, Tetsuya Yabuuchi, Yusuke Oka, Hiroki Urabe, Yoichiro Suga, Masato Takahashi, Fumito Uneuchi, Hironori Kotsubo, Muneo Shoji, Yasuko Kawaguchi
  • Method for improving therapy for autoimmune diseases such as rheumatoid arthritis
    Patent number: 9421186
    Abstract: In the present invention, a method using a combination of iguratimod or a salt thereof and one or more immunosuppressants is useful as a method for the treatment of autoimmune diseases, and with this method adverse effects are lessened. A pharmaceutical composition containing this combination is useful for the treatment of autoimmune diseases. This method and pharmaceutical composition are useful for the treatment of more severe autoimmune diseases.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: August 23, 2016
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventor: Keiichi Tanaka